Neuroptix Corp. of Acton has successfully raised $18.5 million in its Series B funding round to move closer to clinical trials for its eye test that could be used to diagnose people with Alzheimer’s disease.
The money will be used to continue developing the Neuroptix Sapphire diagnostic platform and related technologies, according to the company.
Inventages, a venture capital firm in Switzerland, the Bahamas and New Zealand that focuses on life-sciences, nutrition and wellness companies, led the investment round that also included Rockport Venture Partners. Rockport is based in Boston and Menlo Park, Calif., and focuses on clean technology companies.
